Chimeric antigen receptor T lymphocyte immunotherapy of neuroblastoma
10.3760/cma.j.issn.1673-4408.2017.02.015
- VernacularTitle:嵌合抗原受体T淋巴细胞治疗神经母细胞瘤的研究进展
- Author:
Jiaying DOU
- Keywords:
Chimeric antigen receptor T lymphocyte immunological therapy;
Neuroblastoma;
Ganglioside
- From:
International Journal of Pediatrics
2017;44(2):132-134
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T lymphocyte immunological therapy (CAR-T)is a new oncologic immunotherapy in recent years,which has been widely used in patients with leukemia and lymphoma and achieved a certain effect.Neuroblastoma is one of the most common extracranial solid tumors in children and over 50％ of patients have metastatic recurrence when first diagnosed.The prognosis for the high-risk neuroblastoma remains poor at the moment and it's time to look for new treatments.In this review,we summarize the basic structure and development of CAR-T,discuss the principles and risks of CAR-T in the treatment of neuroblastoma,and give an outlook to CAR-T in the treatment of solid tumors.
